Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Sanofi-Aventis |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00064428 |
The purpose of this research study is to determine the efficacy and safety of fondaparinux (Arixtra) in preventing death and repeat heart attacks and their complications.
Condition | Intervention | Phase |
---|---|---|
Myocardial Infarction |
Drug: fondaparinux sodium Drug: heparin Drug: Glucose-insulin-potassium (GIK) |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Safety and Efficacy Trial Evaluating Fondaparinux Use in a Broad Range of Patients With ST Segment Elevation Acute MI |
Ages Eligible for Study: | 21 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion criteria:
Study ID Numbers: | EFC5112, SR90107 |
Study First Received: | July 8, 2003 |
Last Updated: | September 12, 2006 |
ClinicalTrials.gov Identifier: | NCT00064428 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Acute Myocardial Infarction |
Heart Diseases Anticoagulants Myocardial Ischemia Vascular Diseases Fibrinolytic Agents Fondaparinux Cardiovascular Agents Ischemia |
Org 31540 Insulin Calcium heparin Fibrin Modulating Agents Necrosis Infarction Myocardial Infarction Heparin |
Heart Diseases Anticoagulants Molecular Mechanisms of Pharmacological Action Myocardial Ischemia Hematologic Agents Vascular Diseases Fibrinolytic Agents Fondaparinux Cardiovascular Agents Ischemia |
Pharmacologic Actions Org 31540 Fibrin Modulating Agents Necrosis Pathologic Processes Therapeutic Uses Cardiovascular Diseases Infarction Myocardial Infarction |